Sintilimab

Generic Name
Sintilimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2072873-06-2
Unique Ingredient Identifier
8FU7FQ8UPK
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

First Posted Date
2019-09-20
Last Posted Date
2019-09-20
Lead Sponsor
Buhai Wang
Target Recruit Count
20
Registration Number
NCT04096911
Locations
🇨🇳

People's hospital of northern jiangsu, Yangzhou, Jiangsu, China

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

First Posted Date
2019-09-13
Last Posted Date
2019-09-13
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
40
Registration Number
NCT04089657

EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)

Phase 2
Active, not recruiting
Conditions
Nasopharyngeal Carcinoma
Interventions
Drug: Capecitabine
Drug: sintilimab
First Posted Date
2019-08-28
Last Posted Date
2023-06-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
110
Registration Number
NCT04072107
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

First Posted Date
2019-08-22
Last Posted Date
2020-02-10
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
36
Registration Number
NCT04065282
Locations
🇨🇳

First Affiliated Hospital of Zhejiang University, Zhejiang, China

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization

First Posted Date
2019-08-22
Last Posted Date
2019-08-22
Lead Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Target Recruit Count
29
Registration Number
NCT04065737
Locations
🇨🇳

Shanghai ninth people's hospital, Shanghai, Shanghai, China

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Phase 2
Completed
Conditions
Extensive Disease Small Cell Lung Cancer
Interventions
Drug: Sintilimab
First Posted Date
2019-08-14
Last Posted Date
2023-06-28
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
42
Registration Number
NCT04055792
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Phase 2
Not yet recruiting
Conditions
Peripheral T-cell Lymphoma
Interventions
Drug: Sintilimab
Drug: Chidamide
Drug: Azacidine
First Posted Date
2019-08-12
Last Posted Date
2021-03-09
Lead Sponsor
Peking University
Target Recruit Count
30
Registration Number
NCT04052659
Locations
🇨🇳

Beijing, Beijing, Beijing, China

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

First Posted Date
2019-06-18
Last Posted Date
2024-07-15
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
84
Registration Number
NCT03989336
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

First Posted Date
2019-05-13
Last Posted Date
2022-07-19
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
30
Registration Number
NCT03946969
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

First Posted Date
2019-05-03
Last Posted Date
2022-06-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
55
Registration Number
NCT03936452
Locations
🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy